PharmaGenesis London, London, London, UK.
Oxford PharmaGenesis Ltd, Oxford, UK.
BMJ Open. 2019 Jun 20;9(6):e028655. doi: 10.1136/bmjopen-2018-028655.
Academical and not-for-profit research funders are increasingly requiring that the research they fund must be published open access, with some insisting on publishing with a Creative Commons Attribution (CC BY) licence to allow the broadest possible use. We aimed to clarify the open access variants provided by leading medical journals and record the availability of the CC BY licence for commercially funded research.
We identified medical journals with a 2015 impact factor of ≥15.0 on 24 May 2017, then excluded from the analysis journals that only publish review articles. Between 29 June 2017 and 26 July 2017, we collected information about each journal's open access policies from their websites and/or by email contact. We contacted the journals by email again between 6 December 2017 and 2 January 2018 to confirm our findings.
Thirty-five medical journals publishing original research from 13 publishers were included in the analysis. All 35 journals offered some form of open access allowing articles to be free-to-read, either immediately on publication or after a delay of up to 12 months. Of these journals, 21 (60%) provided immediate open access with a CC BY licence under certain circumstances (eg, to specific research funders). Of these 21, 20 only offered a CC BY licence to authors funded by non-commercial organisations and one offered this option to any funder who required it.
Most leading medical journals do not offer to authors reporting commercially funded research an open access licence that allows unrestricted sharing and adaptation of the published material. The journals' policies are therefore not aligned with open access declarations and guidelines. Commercial research funders lag behind academical funders in the development of mandatory open access policies, and it is time for them to work with publishers to advance the dissemination of the research they fund.
学术性和非营利性研究资助者越来越要求他们资助的研究必须以开放获取的方式发表,其中一些要求以知识共享署名(CC BY)许可证发表,以允许最广泛的使用。我们旨在阐明主要医学期刊提供的开放获取变体,并记录商业资助研究的 CC BY 许可证的可用性。
我们于 2017 年 5 月 24 日确定了 2015 年影响因子≥15.0 的医学期刊,然后从分析中排除了仅发表综述文章的期刊。在 2017 年 6 月 29 日至 7 月 26 日期间,我们从各期刊的网站和/或通过电子邮件联系收集了有关每个期刊开放获取政策的信息。我们于 2017 年 12 月 6 日至 2018 年 1 月 2 日再次通过电子邮件联系期刊以确认我们的发现。
共有来自 13 家出版商的 35 种发表原创研究的医学期刊被纳入分析。所有 35 种期刊都提供了某种形式的开放获取,使文章可以免费阅读,要么在发表时立即免费阅读,要么在最多 12 个月的延迟后免费阅读。在这些期刊中,有 21 种(60%)在特定情况下(例如,对特定的研究资助者)提供了即时开放获取和 CC BY 许可证。在这 21 种期刊中,有 20 种仅向非商业组织资助的作者提供 CC BY 许可证,有 1 种向任何需要的资助者提供此选项。
大多数领先的医学期刊不为报告商业资助研究的作者提供允许不受限制地共享和改编已发表材料的开放获取许可证。因此,期刊的政策不符合开放获取声明和指南。商业研究资助者在制定强制性开放获取政策方面落后于学术资助者,现在是他们与出版商合作推进他们资助的研究传播的时候了。